Astria Therapeutics, INC

Astria Therapeutics, Inc. has completed its merger with BioCryst Pharmaceuticals, Inc., becoming a wholly-owned subsidiary and delisting from Nasdaq.

Astria Therapeutics stockholders have approved the acquisition by BioCryst Pharmaceuticals, with the merger expected to close around January 23, 2026.

Astria Therapeutics, Inc. is facing two lawsuits alleging negligence and misrepresentation regarding its merger with BioCryst Pharmaceuticals, Inc.

Astria Therapeutics announced its third quarter 2025 financial results and provided a corporate update, including the expected Q1 2026 closing of its acquisition by BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals will acquire Astria Therapeutics for approximately $920 million in cash and stock, expanding its hereditary angioedema portfolio with late-stage asset navenibart.

Astria Therapeutics has licensed its investigational HAE therapy, navenibart, to Kaken Pharmaceutical for development and commercialization in Japan, securing an upfront payment and extending its cash runway into 2028.

Astria Therapeutics reports increased net loss in Q3 2025, driven by R&D for Navenibart and STAR-0310, while progressing towards a BioCryst merger and securing a Japan licensing deal.

Astria Therapeutics reported increased losses in Q2 2025 but highlighted significant clinical progress for its lead drug candidates, navenibart and STAR-0310, and extended its cash runway into 2028 through a new licensing deal.

Astria Therapeutics reports a net loss of $33.7 million for Q1 2025, driven by increased research and development expenses, while progressing its navenibart and STAR-0310 clinical programs.

Astria Therapeutics reported its third quarter 2024 financial results, highlighting progress in its clinical programs for navenibart and STAR-0310.

Astria Therapeutics' Q2 2024 report highlights positive clinical trial results for their lead drug candidate, navenibart, and outlines plans for further development of their pipeline.

Astria Therapeutics reported a net loss of $19.9 million for the first quarter of 2024, while highlighting progress in its clinical programs for STAR-0215 and STAR-0310.

Astria Therapeutics highlights clinical advancements in navenibart for hereditary angioedema and STAR-0310 for atopic dermatitis in its 2024 annual report, alongside financial details and future outlook.

Astria Therapeutics, a biopharmaceutical company, released its full year 2023 results, highlighting progress in its clinical development programs for allergic and immunological diseases.

Jonathan Violin, a director of Astria Therapeutics, Inc., reported the disposition of all his common stock and stock options following the company's merger with BioCryst Pharmaceuticals, Inc.

Astria Therapeutics' Chief Medical Officer, Christopher Morabito, received cash for his in-the-money stock options following the company's merger with BioCryst Pharmaceuticals.

Astria Therapeutics CEO Jill C. Milne reports changes in beneficial ownership following the company's merger with BioCryst Pharmaceuticals, Inc.

Astria Therapeutics' Chief Business Officer, Andrea Matthews, received a significant cash payout for her in-the-money stock options following the company's merger with BioCryst Pharmaceuticals.

Astria Therapeutics Director Anthony Gregg Lapointe reported the cancellation of in-the-money stock options for cash following the company's merger with BioCryst Pharmaceuticals.

Astria Therapeutics' Chief Commercial Officer, Andrew Komjathy, reported the disposition of all his beneficial holdings in Astria common stock and stock options following the company's merger with BioCryst Pharmaceuticals.

Astria Therapeutics, Inc. stockholders will vote on a proposed merger with BioCryst Pharmaceuticals, Inc., offering a mix of cash and stock valued at a premium.

Astria Therapeutics will hold its annual stockholders meeting on June 11, 2025, to elect directors, approve a stock incentive plan amendment, ratify the appointment of Ernst & Young LLP, and conduct an advisory vote on executive compensation.

Astria Therapeutics is holding its 2025 Annual Meeting of Stockholders on June 11, 2025, to vote on key proposals including the election of directors and an amendment to the company's stock incentive plan.

Astria Therapeutics will hold its annual stockholders meeting on June 5, 2024, to vote on director elections, a stock incentive plan amendment, auditor ratification, and executive compensation.

Astria Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 5, 2024, to vote on director elections, an amended stock incentive plan, ratification of the accounting firm, and executive compensation.

Perceptive Advisors and related entities have reported zero beneficial ownership in Astria Therapeutics following its acquisition by BioCryst.

Magnetar Financial and its affiliates report the cancellation of all 3.43 million Astria Therapeutics shares following the company's merger at $8.55 per share.

Magnetar Financial and its affiliates have reported a 5.87% beneficial ownership in Astria Therapeutics, Inc., acquired for merger arbitrage purposes following the BioCryst merger announcement.

Perceptive Advisors and its affiliates have entered into a voting agreement to support BioCryst Pharmaceuticals' acquisition of Astria Therapeutics.

Glazer Capital, LLC and Paul J. Glazer have reported a 6.61% beneficial ownership stake in Astria Therapeutics, Inc. as of December 31, 2025.

Glazer Capital, LLC and Paul J. Glazer have reported a beneficial ownership of 5.53% in Astria Therapeutics, Inc. common stock.

Vestal Point Capital, LP and Ryan Wilder have reported a shared beneficial ownership of 8.8% in Astria Therapeutics, Inc., totaling 4,956,000 shares.

Forbion Growth III PA B.V. and related entities report 0% beneficial ownership in Astria Therapeutics, Inc. common stock.

FMR LLC and Abigail P. Johnson report a 2.2% beneficial ownership of Astria Therapeutics Inc. common stock as of October 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a continued 9.1% beneficial ownership in Astria Therapeutics Inc. common stock.